Thank Steve. you,
agreement. NRX-XXX all So $XX suicidality, data remains depression on as the first delivery to our of near Steve the shared with million the payment with phone, in of sufficient our you term trigger priority bipolar partnership for milestone in
has been As previous in have company clinical and you nature with caution selecting, enroll monitoring patients are The to know, from all of patients a medicine. first trial These the patients. take a suicidal to bipolar a trials vulnerable the life-saving oral pharmaceutical we're anti-depressant depression excluded required of who the high-risk high drugs. these of in care recruiting, population clinical us of of this level potentially
with Safety advised no pleased we And have you adverse events unexpected March, no that and In this population time. safety futility. identified high-risk Board Monitoring occurred you share since now we're Independent the that in Data no that serious to concerns
what say. And on and that which are talk I'm medicine endpoints with trials the from with We've about More in things patient to free another. posted a study reflect one and service, to about are read based or fail measured importantly, clinical which are and psychiatry to depression consistency study paper the about the on succeed I'm complex. scientifically to compliance free-print other key to
metrics safety, the potential has which to engaged give should So in confidence we're the are that submitted quality terms added medication be of us prove in for registration and compliance, the able efficacy. we trial the reliability seeing retention, to drug increased rating we that of the the we're way results measuring that have be we going efficacy confidence identify a trial there. words, in that we to such do it's will is drug other work, we In study know if but don't
at we the on this in reliability treatment; the with to like and three company; ways basis. otherwise enrollment. sites our by efficacy conducted metrics raters the the of at those evaluations, compared and trial to compliance daily namely results of prescribed execution the central as patient concordance study key known I'd number evaluate a lastly, track conducted weekly from inter-rater share Today, We of the to date a of
So first, treatment compliance.
our trials, we've compliance at relief compliance the counts prescribed in visits. of we their pill with this as is from encouraged patients high XX% patient by level believe measured far to symptoms. experiencing as by seen than We're greater So patients key regimen
endpoints to Now endpoints let's trial which trial our relief based reliability. suicidality. on the concordance are inter-rater measured. depression In fail the of with their case, Psychiatry and from talk it's accuracy about control those or the is from are relief either ability
that those at efficacy endpoints. the to refined rely PhD, assess and XXXX, During veteran rating. are used both of on and the to study quarter first ratings master's we validate independent team sites graders, monitor train We of technical raters the each rate our or a the quality the who level ability psychometric of psychometric
from we audio obtained and review psychometric and with each whether the they site. study to rating the get an in-house In of our by raters. the We study information agree every file words, other sites that information see
that rating the We basis required that standard of for scale has score antidepressant study set sites Rating endpoints Scale all MADRS. primary to This recently drugs. standard patient-by-patient on the or the Depression X a requires approved on XX-point FDA is the points Montgomery-Åsberg efficacy measurements within raters from be master reported a
recommended essential felt our looser reliability X-point reducing is Now substantially stricter diminishes studies. that the protocol the than psychiatry statistical site-to-site was we it in the in of the standard But X-point standard literature. we variables to prespecified
very And have population? study people a attribute we fact, with small really measurements variance statistically low we accounted to can In the in be often such how around tight for. a endpoints STABIL-B asked to with obtain significant those endpoint that
interviewed So Today, of meet or we've standard of measure posted blinded language, we documenting X-point XX% also standard. from their in spoken study our trial primary first or clinical patients set which better reliability the enrolled inter-rater a research a sites. is what of results that the XX% in across inter-rater percent XX ratings reliability, report and
in from their In patients, lurasidone. in how other files, we same study This and words, master know ratings our baseline this audio approach have there exceeds the being primary able finding All the clinical rigorous ratings obtained who drug of trials routinely to up also the the to to is pre-specified key we reliability in successfully prove literature should is is and be stacks inter-rater on idea same who's published site raters. substantially our endpoints requirements obtained prove. against We that exceeds the believe that's measuring our to trials. the efficacy no by the efficacy on
substantial we the need to to short recruit of a safety ability time. In period patients meet of over number objectives, order our
previously for recruit in XnHealth may As we the states our initiate in cover to up XX to to with recruitment that patients contracted sufficient a X noted Phase XXXX, program. US we campaign April
a within XX, broadened Science with relationship randomize initiatives by to clinical and announced previously its that's broadened XnHealth similarly the participants trials. has enroll decentralized company to identified them The conducting be treated the CRO to clinical trials
So or process. from sites you let miles the in to treat But somebody results. participate. me up Those In patients. explain most clinical lives They XX study really who XXX that study recruit patients. set those unable measure locations. particular sites is They to trials, miles study away sites
ability to country door of their administer study. patients the order in measure anywhere a in medicine, endpoints in and nearly team the the the to recruit order to Science of investigational XX nurses has to the send
substantially on dependence our is that So brick-and-mortar study sites diminished.
to to on additionally is coordinated who've publicize The of expect broad read be of available depression subscribers, Based that voice-of-a-patient clinical suicidality. articles bipolar efforts, the milestone. that Alvogen a engaged has And all And a reach the on now, and meet trial to welcome these with focus Mighty, the to phone indicated XXX,XXX-plus the end national Mighty year organization The personal near with are will the on data XXXX bipolar their latest XnHealth community. press sharing we you
our of broader the And we've know, formulation D-cycloserine NRX-XXX bipolar and public for you combination. talking investors impact pandemic. lurasidone depression, this we XXXX to about tail drug important the potential of the in of COVID explained As on began it's to also combined applications class of the recognize March what
two the drugs, between receptors At unique in we discover different the NRX-XXX, synergies those brain. and chemical NMDA X-HTXA-targeted being
Specifically potential adverse new effectively component a of potent creating an each with events the therapy the effect safety block that advantageous profile. other,
Additionally, effective conditions. and D-cycloserine doses may critical we've in various which the be identified at patented
a the the depressive NMDA at have system portfolio bipolar in now have are discoveries and of of which our been the depression, our at to and of of core patents major discoveries nervous issued core related resulted world, XX These disorder, PTSD, around These company central treatment XX other of platform. the conditions.
PTSD. or Now agreement bipolar or containing suicidality, without with outside NMDA one stress additional such NRx that or depression or anticipates the combination for D-cycloserine antidepressants ingredients with or more depression as the antagonists other with chronic post-traumatic of use disorder products anti-psychotic and will Alvogen develop in field pain
announced carrying more bipolar week, episodes Apkarian, licensure therapy. of use the treatment approximately D-cycloserine In depression. and million contrast, X chronic of Last disorder the than pain. of chronic for we live in are Professor of million Americans the live XX Americans with pain patent, with There who
other who years. live as Those medications; no of Just bipolar electric with suicidality on risks to frequently chronic those over have therapy. become few dependent the visible approved than opioid-based with tragically past which depression, are shock have all treatments the pain
the the evidence Just to House more weeks annually. decreasing website, the and peripheral are of pain with between the White for clinical that who and announced documenting on nervous that posted the paper scientific the demonstrates system a than our central Americans see which interrupts research, extensive D-cycloserine while a which literature, and potentially from We've opioids craving now step you XXX,XXX can those afflicted years early pain. died at chronic pathway pain sensors few nonclinical ago, XX each opioids
NRX-XXX unique shareholders. peer-reviewed that not is that We've studies affords is opportunity neurotoxic not for and We pain for recently published a addictive. NRX-XXX documenting believe and chronic our
were accepted When drugs innovative, a generic not wisdom that bipolar treatment for At analgesic pain. opioids. widely suggested began our work chronic we opioids compete that non-addictive, could depression, time, and market in with predominant effectively
more and series, a creates non-addictive, health the an public policy billion quite for for a public popular awareness, litigation, recent widespread than $XX as opportunity the Today, Today, and pain, reflected $XXX an is different. the shift overwhelming opioids in unique multi-jurisdictional billion is press, treatments market in to and XXXX. movement against chronic established documents television use of by grow situation that expected non-neurotoxic to
a award $X statistically pain. this of funding Of threshold XXXX several Northwestern million is University to with congressionally a research D-cycloserine Group published DOD D-cycloserine. in dose Department portfolio. study XXX-milligram in pain by daily hundred that in by the directed Defense also medical chronic US our recognition patients predicted by program Research dose patent acted study University The That's of identified reduction key on finding to of the at a importance Northwestern the that the significant scores
As a anticipated is shown. approval already chronic rapid on trial efficacy be drug key investment near ingredients therapy, are clinicaltrials.gov, the this large provide our potential the results to the in shown in of D-cycloserine, our public in to and completely patient non-dilutive complete path recruitment study the pain to shareholders, has future. Thus, a drug, namely using for
of treat chronic may The lurasidone independently component our drug also pain.
previously As an on rationale with paper scientific recently our investigational carrying by D-cycloserine and with Phase program in use cohorts. is to pain completed posted website week, of on Schnitzer This we're chronic for for of treatments Professor manufacturing announced, the pain. for outlined in that The and article commercial of their review FDA treat XXXX we've X our and is opening published the file NRX-XXX new chronic we've drug NRX-XXX. the
In brief, DCS craving drug which decreasing has decreasing is response and pain in: demonstrated in one, triggered opioid NMDA pain body; that's no in evidence receptors for is and with nonclinical antagonist two, drugs act to both the pain, clinical that by doses, that the threshold the early non-addictive and above D-cycloserine, efficacy extensive susceptible non-neurotoxic.
evidence PTSD Phase or clinical PTSD, NRX-XXX indication pure stress post-traumatic for NMDA in an that antagonist commence with drug disorder plan planning to We XXXX. to shared PTSD rationale Regarding treating that nonclinical for with memory the additional investigate you in previously in we've X trial with and and associated that decreases as studies. DCS identified PTSD
to I summary, depression. believe solidifies patients progress with reach suicidal our this ability In our bipolar quarter
of evidence executed our we've the effectively results shown that blinded, and monitored. While ongoing remain being trial scientific trial the rigorously is
chronic expanded future Additionally, the for has readouts. growth opportunity our near-term program data with tenfold the company's market company positions pain and
medical billion $XXX patients than market more needs. address while programs unmet opportunity with serving Our in significant
our to like continued and most your investigators, my I'd support. express importantly, the shareholders team, NRX to always, As patients, you, gratitude trial clinical the the for
Voorhees will discuss our financial now Seth performance.
